Opportunity Information: Apply for CDC RFA PS16 1602
Apply for CDC RFA PS16 1602
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "Perinatal Hepatitis B Prevention Program Auxiliary Prevention Projects" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.270 Adult Viral Hepatitis Prevention and Control.
- This funding opportunity was created on Apr 16, 2015 and posted on Apr 16, 2015.
- Applicants must submit their applications by Jun 15, 2015 Electronically submitted applications must be submitted no later than 1159 p.m., ET, on the listed application due date.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $1,200,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $120,000.00 in funding.
- The number of recipients for this funding is limited to 5 candidate(s).
- Eligible applicants include: Special district governments County governments State governments City or township governments.
- Eligible Applicants are The current 64 grantees with established Perinatal Hepatitis B Prevention Programs (PHBPPs) that are funded through CDC RFA IP13 1301, which are the 50 state health departments or their bona fide agents, the District of Columbia, New York City, Philadelphia, Houston, Chicago, and San Antonio, the Commonwealth of Puerto Rico, the Virgin Islands, the Commonwealth of Northern Marianna Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau. Eligibility is limited to those jurisdictions with existing PHBPPs, as it is only possible to carry out the activities of the FOA with existing PHBPPs. Through grants to public health immunization programs, CDC created the U.S. PHBPP in 1990 to accelerate progress toward the elimination of perinatal Hepatitis B virus transmission. The current 64 grantees with established PHBPPs are funded through CDC RFA IP13 1301, which are the 50 state health departments or their bona fide agents, the District of Columbia, New York City, Philadelphia, Houston, Chicago, and San Antonio, the Commonwealth of Puerto Rico, the Virgin Islands, the Commonwealth of Northern Marianna Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau. PHBPPs identify pregnant Hepatitis B infected pregnant women (as determined by Hepatitis B surface antigen positive HBsAg) and ensure their infants receive timely immunoprophylaxis and post vaccination serologic testing.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Perinatal Hepatitis B Prevention Program (PHBPP) Auxiliary Prevention Projects opportunity (CDC RFA PS16-1602) is a CDC cooperative agreement designed to strengthen and modernize existing jurisdictional perinatal hepatitis B prevention efforts. Its overall aim is to advance the HHS Viral Hepatitis Action Plan (2014-2016) by making sure pregnant people with hepatitis B infection are found and reported in time for their newborns to receive correct, timely post-exposure prophylaxis; by improving how consistently infants receive post-vaccination serologic testing (PVST); and by improving data collection so CDC and jurisdictions can better understand infant outcomes and the factors that drive transmission or vaccine response.
The core outcomes CDC is seeking are threefold: (1) increased identification of hepatitis B surface antigen (HBsAg)-positive pregnant women compared to what is expected/estimated in the jurisdiction, (2) higher rates of timely PVST for infants born to identified hepatitis B-infected mothers (with emphasis on PVST completion by 12 months and no later than 18 months), and (3) stronger assessment of demographic and clinical factors linked to infant outcomes, including factors associated with perinatal transmission and vaccine non-response. In practical terms, the projects are meant to close the gap between how many HBV-infected pregnant women are likely present and how many are actually captured by public health programs, while also ensuring the infant follow-up system works reliably through vaccination completion, PVST, and appropriate next steps (revaccination for non-responders and linkage to care for infected infants).
A major emphasis of the announcement is collaboration and service integration, both within health departments and with outside partners, to reduce duplication and prevent missed opportunities. Applicants are encouraged to build internal linkages with other CDC-funded programs to improve identification and reporting of HBV-infected pregnant women, screen household and sexual contacts for hepatitis B, vaccinate susceptible contacts, refer people with chronic HBV for medical care and treatment, and report infants and contacts with chronic infection to the National Notifiable Diseases Surveillance System (NNDSS). Beyond CDC-funded programs, jurisdictions are also encouraged to partner with external organizations such as commercial laboratories, health systems, other federal agencies, nonprofit organizations, and professional societies, particularly where those relationships can improve case finding, reporting timeliness, follow-up, and data completeness.
The strategies and activities in the logic model focus on three operational areas. First is improved identification of HBV-infected pregnant women, with specific encouragement to use capture-recapture or similar methods to cross-check multiple data sources (for example, commercial lab test results for pregnant patients, newborn metabolic screening data, immunization registry records, and other surveillance sources) to locate mothers and infants who should be in PHBPP case management but are not. Provider training is another key activity here, especially for clinicians and facilities involved in deliveries where prenatal reporting did not occur, to reinforce the importance of prompt reporting and enrollment in case management so newborn prophylaxis and follow-up are not delayed.
Second is improving PVST among case-managed infants. The FOA stresses enhanced tracking and follow-up procedures, including prioritizing infants at higher risk of transmission (notably those born to mothers who are hepatitis B e antigen positive or who have very high viral loads, defined in the announcement as at least 10^6 copies/mL when such lab results are available). Jurisdictions are also expected to identify barriers that prevent PVST completion and use that information to help define and model best practices. The intended short-term effect is higher PVST rates, leading to more timely identification of infants who did not respond to vaccination (so they can be revaccinated) and earlier identification/linkage to care for infants who are infected. The longer-term public health payoff described is reduced perinatal and horizontal HBV transmission and, ultimately, fewer HBV-related deaths later in life from cirrhosis or liver cancer.
Third is strengthening surveillance and analytic capacity to determine which demographic and clinical factors are associated with perinatal HBV transmission and vaccine response. Awardees are expected to collect and report standardized data on mothers and infants, explicitly including information related to maternal antiviral therapy, and to submit these data to CDC for analysis. CDC then uses the submitted data to examine patterns, risk factors, and outcome associations that can guide improvements in policy and practice.
Performance measurement is a central part of the award structure. CDC’s evaluation approach focuses on tracking (1) the proportion of HBV-infected pregnant women identified relative to estimated burden and compared with prior years, (2) the proportion of infants receiving timely PVST by 12 and 18 months compared with prior years, along with documented barriers and potential best practices, and (3) maternal and infant demographic/clinical factors associated with infant outcomes. Applicants must also describe their own evaluation and performance monitoring plan, including how they will track progress, manage reporting, and conduct data collection sufficient to support the required measures.
Because this is a cooperative agreement, CDC describes substantial ongoing involvement beyond routine grants management. Monitoring and accountability include regular communication, site visits, and review of work plans, performance reports, and financial reports. CDC also expects to assess whether awardee data systems are adequate for generating credible reports, whether work plans are feasible within the proposed budgets, and whether performance levels and timelines are on track; CDC may work with awardees to adjust work plans based on results, evaluation findings, or budget changes. On the support side, CDC plans frequent conference calls, targeted technical assistance from subject matter experts in perinatal HBV and epidemiology/public health, facilitation of information sharing across awardees, and CDC-led analysis of submitted jurisdictional data.
Eligibility is limited and tightly defined: only the 64 existing PHBPP jurisdictions already funded under CDC RFA IP13-1301 may apply (including all state health departments or bona fide agents, select large cities, DC, and several U.S. territories and freely associated states). This restriction reflects the expectation that applicants already have the baseline PHBPP infrastructure needed to execute these auxiliary projects, such as case management systems, reporting pathways, and relationships with birthing facilities and immunization programs.
The funding profile described is relatively small and targeted: an estimated total of $1.2 million across about five awards, with an award floor of $40,000 and ceiling of $120,000, and no cost sharing or matching requirement. Awards are intended to support discrete enhancements like improved data matching and case finding, strengthened follow-up workflows, provider training, and expanded data collection and reporting capacity rather than building a PHBPP from scratch. Applicants are expected to demonstrate they have (or can quickly assemble) the organizational capacity to plan and manage these improvements, including evaluation expertise, performance monitoring, financial and administrative management, personnel management, and procurement/contracting ability. A specific capacity expectation called out is prior or ongoing collaboration with commercial laboratories, since lab data are a major lever for identifying unreported HBV-positive pregnant women.
In short, this opportunity funds a small number of existing PHBPP jurisdictions to run focused “auxiliary” projects that tighten case finding, improve infant follow-up through PVST, and generate better mother-infant data for analysis. The near-term goal is higher identification and higher PVST completion; the long-term goal is fewer perinatal and early-life HBV infections and fewer severe HBV-related outcomes later in life through better prevention, earlier detection, and stronger linkage to care.
FAQs: Perinatal Hepatitis B Prevention Program (PHBPP) Auxiliary Prevention Projects (CDC RFA PS16-1602)
What is the PHBPP Auxiliary Prevention Projects opportunity (CDC RFA PS16-1602)?
This opportunity is a CDC cooperative agreement that funds targeted “auxiliary” projects to strengthen and modernize existing jurisdictional Perinatal Hepatitis B Prevention Program (PHBPP) activities. The focus is on closing gaps in case finding, improving infant follow-up (including post-vaccination serologic testing, or PVST), and improving data collection and analysis related to mother-infant outcomes.
What public health goal is this funding intended to support?
The projects are intended to advance the HHS Viral Hepatitis Action Plan (2014-2016) by helping jurisdictions find and report pregnant people with hepatitis B infection in time for newborns to receive correct and timely post-exposure prophylaxis, improving PVST completion for infants, and strengthening data collection so CDC and jurisdictions can better understand infant outcomes and the factors that influence transmission or vaccine response.
What are the main outcomes CDC is seeking?
CDC identifies three core outcomes: (1) increased identification of hepatitis B surface antigen (HBsAg)-positive pregnant women compared to what is expected/estimated in the jurisdiction, (2) higher rates of timely PVST for infants born to identified hepatitis B-infected mothers (with an emphasis on completion by 12 months and no later than 18 months), and (3) stronger assessment of demographic and clinical factors linked to infant outcomes, including factors associated with perinatal transmission and vaccine non-response.
What does “closing the gap” mean in practical terms?
It refers to narrowing the difference between the number of HBV-infected pregnant women who are likely present in a jurisdiction (estimated burden) and the number actually identified and captured by public health case management. It also includes ensuring the infant follow-up system reliably supports vaccination completion, PVST, and appropriate next steps (revaccination for non-responders and linkage to care for infected infants).
Who is eligible to apply?
Eligibility is limited to the 64 existing PHBPP jurisdictions already funded under CDC RFA IP13-1301. This includes state health departments or bona fide agents, select large cities, Washington, DC, and several U.S. territories and freely associated states.
Why is eligibility restricted to existing PHBPP jurisdictions?
The announcement expects applicants to already have baseline PHBPP infrastructure in place (such as case management systems, reporting pathways, and relationships with birthing facilities and immunization programs). The funding is meant for enhancements to an existing program, not to build a PHBPP from scratch.
How much funding is available?
The estimated total funding is $1.2 million across about five awards.
What are the minimum and maximum award amounts?
The award floor is $40,000 and the award ceiling is $120,000.
Is cost sharing or matching required?
No cost sharing or matching requirement is described for this opportunity.
What types of projects or enhancements are these funds meant to support?
The funding is intended to support discrete improvements such as improved data matching and case finding, strengthened follow-up workflows for infants, provider training, and expanded data collection and reporting capacity.
What are the three main operational areas described in the logic model?
The strategies and activities are organized around: (1) improved identification of HBV-infected pregnant women, (2) improved PVST among case-managed infants, and (3) strengthened surveillance and analytic capacity to understand which demographic and clinical factors are associated with perinatal transmission and vaccine response.
How does the FOA suggest jurisdictions improve identification of HBV-infected pregnant women?
Jurisdictions are encouraged to use capture-recapture or similar methods to cross-check multiple data sources to find mothers and infants who should be in PHBPP case management but are not. Example sources listed include commercial lab test results for pregnant patients, newborn metabolic screening data, immunization registry records, and other surveillance sources.
What role does provider training play in these projects?
Provider training is highlighted as a key activity, especially for clinicians and facilities involved in deliveries where prenatal reporting did not occur. The goal is to reinforce prompt reporting and enrollment in case management so newborn prophylaxis and follow-up are not delayed.
What is PVST, and why is it emphasized?
PVST stands for post-vaccination serologic testing. The FOA emphasizes PVST because it helps confirm whether an infant responded to hepatitis B vaccination and helps identify infants who may be infected. The announcement particularly stresses completing PVST by 12 months and no later than 18 months.
How does the FOA recommend improving PVST completion?
The FOA stresses enhanced tracking and follow-up procedures, including prioritizing infants at higher risk of transmission. It also expects jurisdictions to identify barriers that prevent PVST completion and use what they learn to help define and model best practices.
Which infants are specifically called out as higher priority for follow-up?
Infants at higher risk of transmission are noted, especially those born to mothers who are hepatitis B e antigen positive or who have very high viral loads, defined in the announcement as at least 10^6 copies/mL when those lab results are available.
What are the expected short-term effects of improving PVST rates?
The FOA describes that higher PVST rates should lead to earlier identification of infants who did not respond to vaccination (so they can be revaccinated) and more timely identification and linkage to care for infants who are infected.
What longer-term outcomes does CDC associate with these projects?
The longer-term payoff described includes reduced perinatal and horizontal HBV transmission and, ultimately, fewer HBV-related deaths later in life from cirrhosis or liver cancer.
What does the FOA mean by “strengthening surveillance and analytic capacity”?
It means improving the ability to collect, standardize, and report mother-infant data so CDC and jurisdictions can analyze patterns and identify which demographic and clinical factors are associated with infant outcomes, including perinatal HBV transmission and vaccine non-response.
What standardized data elements are explicitly mentioned?
The FOA explicitly includes information related to maternal antiviral therapy as part of the standardized data that awardees are expected to collect and report to CDC.
What happens to the data jurisdictions submit?
CDC uses submitted jurisdictional data to analyze patterns, risk factors, and associations with outcomes, with the intent of guiding improvements in policy and practice.
What performance measures does CDC emphasize for this cooperative agreement?
CDC’s evaluation approach focuses on: (1) the proportion of HBV-infected pregnant women identified relative to estimated burden and compared with prior years, (2) the proportion of infants receiving timely PVST by 12 and 18 months compared with prior years, along with documented barriers and potential best practices, and (3) maternal and infant demographic/clinical factors associated with infant outcomes.
Do applicants need to propose their own evaluation plan?
Yes. Applicants must describe an evaluation and performance monitoring plan, including how they will track progress, manage reporting, and conduct data collection sufficient to support the required measures.
What does it mean that this opportunity is a “cooperative agreement”?
The FOA describes substantial ongoing CDC involvement beyond routine grants management. This includes monitoring and accountability activities (regular communication, site visits, and review of work plans, performance reports, and financial reports) and active support (frequent conference calls, targeted technical assistance, facilitation of information sharing across awardees, and CDC-led analysis of submitted data).
How does CDC describe its monitoring and accountability expectations?
CDC expects to review work plans, performance reports, and financial reports; conduct regular communications and site visits; assess whether awardee data systems can produce credible reports; evaluate whether work plans are feasible within proposed budgets; and determine whether performance levels and timelines are on track. CDC may also work with awardees to adjust work plans based on results, evaluation findings, or budget changes.
What kinds of collaboration are encouraged?
A major emphasis is collaboration and service integration within health departments and with external partners to reduce duplication and prevent missed opportunities. Applicants are encouraged to build internal linkages with other CDC-funded programs and also to partner with organizations such as commercial laboratories, health systems, other federal agencies, nonprofit organizations, and professional societies.
What specific activities are mentioned for integration with other programs?
Activities include improving identification and reporting of HBV-infected pregnant women; screening household and sexual contacts; vaccinating susceptible contacts; referring people with chronic HBV for medical care and treatment; and reporting infants and contacts with chronic infection to the National Notifiable Diseases Surveillance System (NNDSS).
Why are commercial laboratories specifically important in this FOA?
The FOA highlights lab data as a major lever for identifying unreported HBV-positive pregnant women, and it calls out prior or ongoing collaboration with commercial laboratories as a specific capacity expectation.
What organizational capacities are applicants expected to demonstrate?
Applicants are expected to show they have (or can quickly assemble) the capacity to plan and manage improvements, including evaluation expertise, performance monitoring, financial and administrative management, personnel management, and procurement/contracting ability.
Does the FOA focus only on finding pregnant people with HBV?
No. While improved identification is a core focus, the FOA also emphasizes infant follow-up through vaccination completion and PVST, next steps for non-responders and infected infants, and improved data collection to understand outcomes and risk factors.
How does this FOA address duplication and missed opportunities?
It encourages collaboration and service integration within health departments and with external partners, and it promotes cross-checking multiple data sources (such as lab results, newborn screening, immunization registries, and surveillance sources) to identify cases that might otherwise be missed.
Browse more opportunities from the same category: Health
Next opportunity: HHS/ACL/NIDILLRR Employment Policy and Measurement CFDA Number 84.133B 3
Previous opportunity: SMART FY 15 Campus Focused Sexual Assault Perpetration Prevention and Education Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA PS16 1602
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA PS16 1602) also looked into and applied for these:
| Funding Opportunity |
|---|
| HHS/ACL/NIDILRR Advanced Rehabilitation Research Training (ARRT) Program Advanced Rehabilitation Research Policy Fellowship CFDA Number 84.133P 5 Apply for ED ACL GRANTS 060915 001 Funding Number: ED ACL GRANTS 060915 001 Agency: Department of Education Category: Health Funding Amount: $150,000 |
| Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships Apply for CDC RFA DP15 1511 Funding Number: CDC RFA DP15 1511 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $4,000,000 |
| Regional AIDS Education and Training Centers Apply for HRSA 15 154 Funding Number: HRSA 15 154 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Research and Methods in Health Statistics Apply for RFA SH 16 001 Funding Number: RFA SH 16 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $100,000 |
| TRANSFORM/PRIMARY HEALTH CARE UNIT (PHCU) Apply for RFA 663 15 000016 Funding Number: RFA 663 15 000016 Agency: Ethiopia USAID Addis Ababa Category: Health Funding Amount: $120,000,000 |
| Ryan White HIV/AIDS Program Part A HIV Emergency Relief Grant Program Apply for HRSA 16 021 Funding Number: HRSA 16 021 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| NIAMS Building Interdisciplinary Research Team (BIRT) Revision Awards (U01, U54, P01, P50, and P60) Apply for RFA AR 09 002 Funding Number: RFA AR 09 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| AHRQ Grant Program for Large Conference Support (R13) and (U13) Apply for PA 06 378 Funding Number: PA 06 378 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $100,000 |
| Development of Comprehensive Drug/Alcohol and Mental Health Treatment Systems for Persons Who are Homeless Apply for TI 09 006 Funding Number: TI 09 006 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $350,000 |
| Grants to Expand Substance Abuse Treatment Capacity for Adult Drug Courts Apply for TI 09 003 Funding Number: TI 09 003 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $300,000 |
| Offender Reentry Program Apply for TI 09 005 Funding Number: TI 09 005 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $400,000 |
| Grants for Primary and Behavioral Health Care Integration Apply for SM 09 011 Funding Number: SM 09 011 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $500,000 |
| Partnerships for Success State and Community Prevention Performance Grant Apply for SP 09 005 Funding Number: SP 09 005 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $2,300,000 |
| Health Promotion and Disease Prevention Apply for HHS 2009 IHS HPDP 0001 Funding Number: HHS 2009 IHS HPDP 0001 Agency: Indian Health Service Category: Health Funding Amount: $100,000 |
| Offender Reentry Program Apply for TI 10 006 Funding Number: TI 10 006 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $400,000 |
| Grants to Expand Substance Abuse Treatment Capacity for Juvenile Treatment Drug Courts Apply for TI 10 004 Funding Number: TI 10 004 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $325,000 |
| Grants to Expand Substance Abuse Treatment Capacity for Adult Drug Courts Apply for TI 10 011 Funding Number: TI 10 011 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $325,000 |
| Mental Health Transformation Grants Apply for SM 10 010 Funding Number: SM 10 010 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $750,000 |
| Grants to Expand Services to Children Affected by Methamphetamine in Families Participating in Family Treatment Drug Court Apply for TI 10 009 Funding Number: TI 10 009 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $370,000 |
| Capacity Building Initiative for Substance Abuse (SA) and HIV Prevention Services for At Risk Racial/Ethnic Minority Young Adults Apply for SP 10 004 Funding Number: SP 10 004 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $300,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA PS16 1602", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.